Search
forLearn
5 / 801 resultslearn NMN
learn PTD-DBM
learn LHA™
learn biovolume 128
Research
5 / 1000+ resultsresearch Hypothalamic lipid metabolism and the control of food intake
The VMH AMPK-SNS-BAT axis may help treat cachexia and obesity.
research Verrucous hemangioma leg: A challenging birthmark
A boy with a rare birthmark called verrucous hemangioma needed careful timing for surgery due to its size and depth.
research A New Look at the 5?-Reductase Inhibitor Finasteride
Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
research Prostaglandin D2 Uses Components of ROS Signaling to Enhance Testosterone Production in Keratinocytes
Prostaglandin D2 increases testosterone production in skin cells through a process involving reactive oxygen species, and antioxidants may help treat hair loss.
research Acupuncture in Polycystic Ovary Syndrome: Potential and Challenge
Acupuncture may improve reproductive and metabolic functions in PCOS without negative side effects, but more research is needed to confirm its effectiveness.
Community Join
5 / 1000+ resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115 start AGA phase 2 trial volunteer in China. The eligible volunteer should be age between 18 to 65, Norwood 3 vertex , 4 and 5. And agree to prevent pregnancy. The trial is leaded by the doctor in Beijing hospital.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.